profit from every $100 of sales.
$0$100
ImmuCell
$10.19-0.68% today
+62.5% in 1 year
1-year low $4.561-year high $11.72
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What ImmuCell sold, what it kept, and what it did with the cash.
Sales went from $18.6 million in 2022 to $27.6 million in 2025, with -$1.04 million of profit last year.
SalesProfit
ImmuCell vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| ImmuCell | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads ImmuCell's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 19 | 17 | 26 | 28 | |
| 8 | 4 | 8 | 11 | |
| -2 | -6 | -2 | 2 | |
| 0 | -3 | 1 | 2 | |
| -2 | -6 | -2 | -1 | |
| -0.32 | -0.75 | -0.26 | -0.12 | |
| 41.2% | 22.1% | 30.0% | 41.4% | |
| -12.4% | -32.9% | -6.2% | 6.0% | |
| -13.4% | -33.1% | -8.1% | -3.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 45 | 44 | 45 | 43 |
| Cash | 6 | 1 | 4 | 4 |
| Total debt | 12 | 17 | 15 | 13 |
| Total liabilities | 14 | 19 | 18 | 15 |
| 30 | 25 | 28 | 27 | |
| 8 | 8 | 8 | 9 | |
| -3.9% | -10.1% | -3.0% | -1.2% | |
| -8.2% | -23.1% | -7.8% | -3.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -2 | -5 | 0 | 2 | |
| 4 | 2 | 0 | 1 | |
| -6 | -7 | -0 | 1 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 2.8×
- 3.3×
- 75.6×
- 47.6×
- 1.3%
- -1.1%
- 0.0%
Profitability
- 41.4%
- 6.0%
- -3.8%
- 17.1%
- 4.1%
- -5.5%
- -3.6%
- -2.4%
- 4.3%
- 11.0%
Growth
- +14.2%
- –
- +1,236.0%
- –
- +4.4%
Financial health
- 2.0×
- 0.49
- 31.0%
- 4.3×
- 4.26
- 1.93
- 0.65
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 44%of 958
Bottom 40%of 888
Top 39%of 889
Top 49%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | 0.21 | 0.05 | +320.0% |
| Mar 4, 2026 | -0.31 | -0.01 | −3,000.0% |
| Nov 13, 2025 | -0.02 | – | – |
| Aug 14, 2025 | 0.06 | – | – |
| May 14, 2025 | 0.16 | – | – |
| Feb 25, 2025 | 0.06 | – | – |
| Nov 13, 2024 | -0.09 | – | – |
| Aug 13, 2024 | -0.20 | – | – |
News
ImmuCell outlines ~$4.5M liquids expansion, targeting more than 3x capacity by end of 2027Seeking Alpha · Aug 14, 2026The newest story we have is from Aug 14, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
39No pass
Philip Fisher
30No pass
Peter Lynch
50No pass
Joel Greenblatt
0No pass
Charlie Munger
20No pass
Terry Smith
21No pass
Questions about ImmuCell
Is ImmuCell a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ImmuCell AI analysis
What does ImmuCell do?
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It is in Biotechnology.
Does ImmuCell pay a dividend?
No. ImmuCell does not pay a dividend at the moment.
Is ImmuCell stock halal?
Yes. ImmuCell passes our halal screen: its business is permitted and its debt is 14% of its market value, under the 30% limit. How we check
How has ImmuCell stock done over the past year?
Up 62.5% over the past twelve months, to $10.19. It traded between $4.56 and $11.72 and is 13.1% below its high.
Who are ImmuCell's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with ImmuCell's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.